Xwell Inc (XWEL)

$1.62

-0.03

(-1.63%)

Market is closed - opens 7 PM, 24 May 2024

Insights on Xwell Inc

  • Decreasing Revenue

    Revenue is down for the last 4 quarters, 8.17M → 7.40M (in $), with an average decrease of 3.2% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -9.91M → -6.58M (in $), with an average increase of 25.3% per quarter

  • Vs A

    In the last 1 year, Agilent Technologies Inc. has given 18.8% return, outperforming this stock by 85.8%

Performance

  • $1.60
    $1.69
    $1.62
    downward going graph

    1.23%

    Downside

    Day's Volatility :5.41%

    Upside

    4.23%

    downward going graph
  • $1.26
    $6.40
    $1.62
    downward going graph

    22.22%

    Downside

    52 Weeks Volatility :80.31%

    Upside

    74.69%

    downward going graph

Returns

PeriodXwell IncIndex (Russel 2000)
3 Months
-17.66%
0.0%
6 Months
-20.06%
0.0%
1 Year
-67.0%
0.0%
3 Years
-88.03%
-20.1%

Highlights

Market Capitalization
6.9M
Book Value
$3.11
Earnings Per Share (EPS)
-6.64
Wall Street Target Price
7.0
Profit Margin
-92.14%
Operating Margin TTM
-62.45%
Return On Assets TTM
-22.04%
Return On Equity TTM
-81.34%
Revenue TTM
30.1M
Revenue Per Share TTM
7.21
Quarterly Revenue Growth YOY
-2.1%
Gross Profit TTM
12.0M
EBITDA
-17.2M
Diluted Eps TTM
-6.64
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Xwell Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 332.1%

Current $1.62
Target $7.00

Company Financials

FY18Y/Y Change
Revenue
50.1M
↑ 2.6%
Net Income
-37.2M
↑ 29.0%
Net Profit Margin
-74.27%
↓ 15.2%
FY19Y/Y Change
Revenue
48.5M
↓ 3.15%
Net Income
-20.5M
↓ 44.82%
Net Profit Margin
-42.32%
↑ 31.95%
FY20Y/Y Change
Revenue
8.4M
↓ 82.72%
Net Income
-92.2M
↑ 349.25%
Net Profit Margin
-1.1K%
↓ 1057.64%
FY21Y/Y Change
Revenue
73.7M
↑ 779.3%
Net Income
3.3M
↓ 103.63%
Net Profit Margin
4.54%
↑ 1104.5%
FY22Y/Y Change
Revenue
55.9M
↓ 24.13%
Net Income
-32.6M
↓ 1074.29%
Net Profit Margin
-58.33%
↓ 62.87%
FY23Y/Y Change
Revenue
30.1M
↓ 46.18%
Net Income
-27.7M
↓ 14.98%
Net Profit Margin
-92.14%
↓ 33.81%
Q4 FY22Q/Q Change
Revenue
7.6M
↓ 29.6%
Net Income
-13.5M
↑ 75.24%
Net Profit Margin
-178.05%
↓ 106.52%
Q1 FY23Q/Q Change
Revenue
7.6M
↑ 0.0%
Net Income
-14.3M
↑ 5.97%
Net Profit Margin
-188.69%
↓ 10.64%
Q2 FY23Q/Q Change
Revenue
8.2M
↑ 8.16%
Net Income
-5.7M
↓ 59.82%
Net Profit Margin
-70.09%
↑ 118.6%
Q3 FY23Q/Q Change
Revenue
7.5M
↓ 8.65%
Net Income
-9.9M
↑ 73.09%
Net Profit Margin
-132.81%
↓ 62.72%
Q4 FY23Q/Q Change
Revenue
7.4M
↓ 0.87%
Net Income
-6.6M
↓ 33.62%
Net Profit Margin
-88.94%
↑ 43.87%
Q1 FY24Q/Q Change
Revenue
7.4M
↑ 0.0%
Net Income
-6.6M
↑ 0.0%
Net Profit Margin
-88.94%
↑ 0.0%
FY18Y/Y Change
Total Assets
30.6M
↓ 53.12%
Total Liabilities
17.4M
↓ 10.06%
FY19Y/Y Change
Total Assets
28.7M
↓ 6.08%
Total Liabilities
31.3M
↑ 79.15%
FY20Y/Y Change
Total Assets
103.1M
↑ 259.05%
Total Liabilities
22.8M
↓ 27.18%
FY21Y/Y Change
Total Assets
127.3M
↑ 23.4%
Total Liabilities
27.3M
↑ 20.07%
FY22Y/Y Change
Total Assets
70.4M
↓ 44.66%
Total Liabilities
22.5M
↓ 17.76%
FY23Y/Y Change
Total Assets
39.0M
↓ 44.63%
Total Liabilities
18.0M
↓ 19.82%
Q4 FY22Q/Q Change
Total Assets
70.4M
↓ 17.12%
Total Liabilities
22.5M
↓ 4.15%
Q1 FY23Q/Q Change
Total Assets
70.4M
↑ 0.0%
Total Liabilities
22.5M
↑ 0.0%
Q2 FY23Q/Q Change
Total Assets
56.6M
↓ 19.65%
Total Liabilities
19.6M
↓ 12.86%
Q3 FY23Q/Q Change
Total Assets
44.6M
↓ 21.27%
Total Liabilities
17.3M
↓ 11.78%
Q4 FY23Q/Q Change
Total Assets
39.0M
↓ 12.47%
Total Liabilities
18.0M
↑ 4.29%
Q1 FY24Q/Q Change
Total Assets
39.0M
↑ 0.0%
Total Liabilities
18.0M
↑ 0.0%
FY18Y/Y Change
Operating Cash Flow
-6.6M
↓ 46.06%
Investing Cash Flow
-1.9M
-
Financing Cash Flow
5.6M
↓ 7.28%
FY19Y/Y Change
Operating Cash Flow
-113.0K
↓ 98.28%
Investing Cash Flow
-2.3M
↑ 21.92%
Financing Cash Flow
1.2M
↓ 79.36%
FY20Y/Y Change
Operating Cash Flow
-25.0M
↑ 22034.51%
Investing Cash Flow
-4.3M
↑ 91.16%
Financing Cash Flow
117.2M
↑ 9962.23%
FY21Y/Y Change
Operating Cash Flow
15.6M
↓ 162.54%
Investing Cash Flow
-5.2M
↑ 18.56%
Financing Cash Flow
6.3M
↓ 94.58%
FY22Y/Y Change
Operating Cash Flow
-24.2M
↓ 254.63%
Investing Cash Flow
-34.8M
↑ 575.78%
Financing Cash Flow
-27.4M
↓ 531.2%
Q4 FY22Q/Q Change
Operating Cash Flow
-6.8M
↓ 22.85%
Investing Cash Flow
-23.9M
↑ 1281.51%
Financing Cash Flow
279.0K
↓ 102.51%
Q1 FY23Q/Q Change
Operating Cash Flow
-6.8M
↑ 0.0%
Investing Cash Flow
-3.3M
↓ 86.24%
Financing Cash Flow
279.0K
↑ 0.0%
Q2 FY23Q/Q Change
Operating Cash Flow
-2.8M
↓ 59.41%
Investing Cash Flow
-480.0K
↓ 85.41%
Financing Cash Flow
-120.0K
↓ 143.01%

Technicals Summary

Sell

Neutral

Buy

Xwell Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Xwell Inc
Xwell Inc
15.97%
-20.06%
-67.0%
-88.03%
-88.03%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
4.89%
8.31%
12.33%
-5.78%
104.26%
Agilent Technologies Inc.
Agilent Technologies Inc.
9.82%
20.73%
18.84%
14.65%
125.81%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
2.82%
20.38%
12.51%
27.75%
117.99%
Danaher Corp.
Danaher Corp.
5.56%
20.68%
16.16%
5.23%
102.99%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
-5.28%
6.61%
12.02%
-6.82%
68.13%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Xwell Inc
Xwell Inc
NA
NA
NA
0.0
-0.81
-0.22
NA
3.11
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
50.24
50.24
4.75
11.05
0.72
0.23
NA
18.93
Agilent Technologies Inc.
Agilent Technologies Inc.
37.03
37.03
2.7
5.5
0.21
0.08
0.01
21.12
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
37.88
37.88
2.81
21.71
0.14
0.05
0.0
119.24
Danaher Corp.
Danaher Corp.
49.0
49.0
3.13
7.61
0.08
0.04
0.0
72.16
Iqvia Holdings Inc.
Iqvia Holdings Inc.
31.35
31.35
1.33
11.08
0.22
0.05
NA
34.82
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Xwell Inc
Xwell Inc
Buy
$6.9M
-88.03%
NA
-92.14%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$42.8B
104.26%
50.24
23.26%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$45.3B
125.81%
37.03
18.35%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$225.3B
117.99%
37.88
14.2%
Danaher Corp.
Danaher Corp.
Buy
$197.4B
102.99%
49.0
18.55%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$41.8B
68.13%
31.35
9.01%

Institutional Holdings

  • Vanguard Group Inc

    2.63%
  • BlackRock Inc

    1.98%
  • Geode Capital Management, LLC

    1.16%
  • State Street Corporation

    0.39%
  • Integrated Wealth Concepts LLC

    0.25%
  • Advisor Group Holdings, Inc.

    0.16%

Company Information

xpresspa group, inc. (nasdaq:xspa) is a health and wellness holding company. xpresspa group’s core asset, xpresspa, is the world’s largest airport spa company, with 57 locations in 23 airports globally (as of january 8, 2018), including one off-airport spa at westfield world trade center in new york city. xpresspa offers services that are tailored specifically to the busy customer. xpresspa is committed to providing exceptional customer experiences with its innovative premium spa services, as well as exclusive luxury travel products and accessories. xpresspa serves almost one million customers per year at its locations in the united states, holland, and the united arab emirates. xpresspa group’s non-core assets include group mobile, infomedia, and an intellectual property assets. to learn more about xpresspa group, visit: www.xpresspagroup.com. to learn more about xpresspa, visit www.xpresspa.com.

Organization
Xwell Inc
Employees
266
CEO
Mr. Scott R. Milford
Industry
Miscellaneous

FAQs